@article{Duijvelaar_2022,<br/><span class="tab"></span> title={Cardiac Safety of Imatinib for the Treatment of COVID-19: A Secondary Analysis of a Randomized,<br/><span class="tab"></span> Double-Blind,<br/><span class="tab"></span> Placebo-Controlled Trial},<br/><span class="tab"></span> volume={80},<br/><span class="tab"></span> ISSN={0160-2446},<br/><span class="tab"></span> url={http://dx.doi.org/10.1097/fjc.0000000000001344},<br/><span class="tab"></span> DOI={10.1097/fjc.0000000000001344},<br/><span class="tab"></span> number={6},<br/><span class="tab"></span> journal={Journal of Cardiovascular Pharmacology},<br/><span class="tab"></span> publisher={Ovid Technologies (Wolters Kluwer Health)},<br/><span class="tab"></span> author={Duijvelaar,<br/><span class="tab"></span> Erik and Vanhove,<br/><span class="tab"></span> Arthur and Schippers,<br/><span class="tab"></span> Job R. and Smeele,<br/><span class="tab"></span> Patrick J. and de Man,<br/><span class="tab"></span> Frances S. and Pinto,<br/><span class="tab"></span> Yigal and Aman,<br/><span class="tab"></span> Jurjan and Bogaard,<br/><span class="tab"></span> Harm Jan},<br/><span class="tab"></span> year={2022},<br/><span class="tab"></span> month=dec,<br/><span class="tab"></span> pages={783–791} }